Spirofurane derivatives

Details Spirofurane derivatives Spirofurane derivatives

1995-06-06

1997-01-14

Berch, Mark L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546 16, 546207, 546242, C07D47110, C07D40506, C07D21144, A61K 31445

Patent

active

055940005

ABSTRACT:
Compounds of general formula I, ##STR1## wherein R.sup.1 represents hydrogen or alkyl C.sub.1-3,
R.sup.2 represents hydrogen, alkyl C.sub.1-6, alkenyl C.sub.3-6 or alkynyl C.sub.3-6,
n and m are integers from 1 to 3, provided that n+m=4, and
one of X and Y represents CH.sub.2 and the other represents CHR.sup.3, C=CHR.sup.4 or C=NR.sup.5, in which
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16 and R.sup.17 are as defined in the specification,
and their salts
are useful as pharmaceuticals, in particular as central muscarinic acetylcholine receptors. The compounds are therefore useful in the treatment of diseases such as presenile and senile dementia, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania and Tourette Syndrome, and also as analgesic agents for use in the treatment of severe painful conditions such as rheumatism, arthritis, and terminal illness.

REFERENCES:
patent: 4735944 (1988-04-01), Bollinger
patent: 4940795 (1990-07-01), Tsukamoto
Takemura et al., Chem. Pharm. Bull. 29, 10, 3019-3025 (1981), "Synthesis and Selective Activity of Cholinergic Agents with Rigid Skeletons".
Coldham et al., Tet. Letters, 29, 41, 5321 (1988), "Stereochemically Control Synthesis of Spirocyclic Lactones and Ethers from N-methyl-4-piperidone and 3-quinuclidinone by Phenylthio Migration".
Shapiro et al., Chem. Ab., 90:20383K, "Synthesis of Nitroxyl Radicals Based on 4-ethyl-4-hydroxy-2,2,6,6-tetramethylpiperidine." (1979).
Azerbaev et al., Chem Abs. 74:111879r "Synthesis of 1,2,5-trimethyl-4-(3-hydroxy-1-propynyl)-4-piperidinol and Its Reactions." (1971).
Azerbaev et al., Chem. Abs. 70:96659r, "Synthesis and Reactions of 2,5-dimethyl-4-(3-methyl-3-hydroxy-1-butynyl)-4-piperidinol." (1968).
Aggleton, J. P., Blindt, H. S., and Candy, J. M. (1989). Working memory in aged rats. Behavioral Neuroscience, 103(5):975-983.
Bartus, R. T., Dean, R. L., and Beer, B. (1980). Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics. Neurobiology of Aging, 1:145-152.
Bartus, R. T. (1985). The cholinergic hypothesis: a historical overview, current perspective, and future directions In: D. S. Olton, E. Gamzu, S. Corkin (Eds.), Memory dysfunctions an integration of animal and human research from preclinical and clinical perspectives, New York: Annals of the New York Academy of Sciences, vol. 444: 332-358.
Becker, R. E. (1991). Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In: R. E. Becker, E. Giacobini (Eds.), Cholinergic basis for Alzheimer therapy, Boston: Birkhauser, 1-22.
Bonner, T. I. (1989). New subtypes of muscarinic acetylcholine receptors. Trends in Pharmacological Sciences, suppl., 11-15.
Christie, J. E., Shering, A., Ferguson, J., and Glen, A. I. M. (1981). Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. British Journal of Psychiatry, 138:46-50.
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, D. A. Schneider, L. S., Whitehouse, P. J., Hoover, T. M. Morris, J. C., Kawas, C. H. Knopman, D. S., Earl, N. L., Kumar, V., and Doody, R. S. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The New England Journal of Medicine, 327(18):1253-1259.
Eagger, S. A., Levy, R., and Sahakian, B. J. (1991). Tacrine in Alzheimer's disease. The Lancet, 337:989-992.
Farlow, M., Gracon, S. I., Hershey, L. A., Lewis, K. W., Sadowsky, C. H., and Dolan-Ureno, J. (1992). A controlled trial of tacrine in Alzheimer's disease. Journal of the American Medical Association, 268(18):2523-2529.
Goyal, R. K. (1989). Muscarinic receptor subtypes: physiological and clinical implications. The New England Journal of Medicine, 321(15):1022-1029.
Katzman, R. (1986). Medical progress: Alzheimer's disease. The New England Journal of Medicine, 314(15):964-973.
Messer, W. S., Bohnett, M., and Stibbe, J. (1990). Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neuroscience Letters, 116, 184-189.
Ordy, J. M., Thomas, G. J., Volpe, B. T., Dunlap, W. P., and Colombo, P. M. (1988). An animal model of human-type memory loss based on aging, lesion, forebrain ischemia, and drug studies with the rat. Neurobiology of Aging, 9:667-683.
Potter, L. T., Pearce, B. D., and Fisher, A. (1990). Selection of cholinergic agents which may improve memory; In: T. Nagatsu (Ed.), Basic, clinical and therapeutic aspects of Alzheimer's and Parkinson's diseases, New York: Plenum Press, 335-340.
Potter, L. T. and Ferrendelli, C. A. (1989). Affinities of different cholinergic agonists for the high and low affinity states of hippocampal M1 muscarine receptors. Journal of Pharmacology and Experimental Therapeutics, 248:974-978.
Raffaele, K. C., Berardi, A., Asthana, S., Morris, P., Schapiro, M. B., Haxby, J. V., and Soncrant, T. T. (1991). Performance improvements in patients with dementia of the Alzheimer type following treatment with the muscarinic cholinergic agonist arecoline.Society for Neuroscience Abstracts, 274.7.
Sitaram, N. and Weingartner, H. (1978). Human serial learning: enhancement with arecholine and choline and impairment with scopolamine. Science, 201:274-276.
Small, G. W. (1992). Tacrine for treating Alzheimer's disease. Journal of American Medical Association, 268(18):2564-2565.
Soncrant, T. T., Greig, N. H., Asthana, S., Shetty, H. U., Daly, E., Raffaele, K. C., Berardi, A., and Haxby, J. V. (1992). Optimizing arecoline-induced improvement in Alzheimer's disease by plasma drug monitoring, Neurobiology of Aging, 13(suppl 1): s131.
Spencer, D. G., Horvath, E., and Traber, J. (1986). Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections. Brain Research, 380:59-68.
Squire, L. R. (1992). Memory and the hippocampus:a synthesis from findings with rats, monkeys, and humans. Psychological Review, 99(2):195-231.
Squire, L. R. and Butters, N. (1992). Neuropsychology of memory (2nd ed.), New York: Guilford Press.
Thomas, G. J. and Ordy, J. M. (1992). Memory: a behavioristic and neuroscientific approach. In: L. R. Squire (Ed.), Neuropsychology of memory (2nd ed.), New York: Guilford Press, 485-495.
Ordy, Neurobiology of Ageing 9, 667-683 (1988).
Welsh, Arch. Neurol. 48, 278-281 (1991).
Gray, TiPS, Suppl, 85-89 (1989).
Asthana, Soc. for Neurosci 21st Annual Meeting New Orleans, LA Nov. 10-15 1991 Abs #274.7.
Bartus, Science, 217, 408 (1982).
Quirion, TiPS, (Suppl) 80-84 (1989).
Mash, Science 228, 1115 (1985).
Pearce, Alzheimers Disease & Related Disorders vol 5, #3, pp. 163-172 (1990).
Washington Post article, Dec. 4, 1991.
Washington Post article, Mar. 19, 1993.
Thompson, New Eng. J. Medicine 323, p. 445.
Kolata, New York Times Article, Jul. 16, 1991.
Nordberg et al. in Alz. Dis & Related Disorders (1989), p. 1169.
Pomara et al, in "Alzheimer's Disease and Related Disorders" (Alan R. Liss, Inc., 1989) pp. 1223-1233.

Affiliated with

Also associated with

Rating

Spirofurane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spirofurane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirofurane derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1388423